Checklist: What regulators always ask about in your study design

Navigating the complex landscape of drug development requires more than just scientific rigor; it demands an unwavering alignment with regulatory expectations from day one. Regulatory agencies, ranging from the FDA and EMA to their regional counterparts, meticulously scrutinize study designs to ensure data integrity, patient safety, and statistical validity before a single subject is enrolled. To avoid costly delays or request for additional information (RFAs) later in the process, investigators must proactively anticipate every question a regulator might ask regarding the architecture of their clinical trial.

Foundational Elements of Study Design

Before diving into specific methodological choices, the foundation of the study protocol must be solid. Regulators always begin their review by verifying that the study design directly addresses the intended therapeutic indications and the primary objectives outlined in the Investigator Brochure or Investigational New Drug (IND) application. The primary endpoint must be clinically meaningful and statistically powered to detect a difference that matters to patients. Furthermore, the selection of study sites and investigators is critical; the design must demonstrate that these entities possess the necessary expertise, infrastructure, and regulatory history to execute the trial successfully. If the design suggests a lack of feasibility or potential for high dropout rates, it raises immediate red flags regarding data reliability.

Population Definition and Inclusion/Exclusion Criteria

One of the most frequently scrutinized areas is the definition of the target population. Regulators ask why specific criteria were chosen and whether they are broad enough to capture the patients who will benefit from the drug while narrow enough to ensure safety and statistical power. They will probe the rationale behind inclusion and exclusion criteria, asking if they are consistent with the disease state, the disease progression, and the comparator arm. For instance, if the study includes patients with unstable conditions, the regulators will question how this affects the safety assessment. The design must clearly articulate how the selected population aligns with the product's labeling and the intended market, ensuring that the results are generalizable to the intended user group without introducing confounding variables that obscure the treatment effect.

Control Selection and Comparator Justification

There is no single "correct" control, but regulators will always ask why a specific control was selected over others. The design must justify the choice of an active control, placebo, or historical control, explaining how it represents the standard of care or the best available alternative. If a study uses a non-inferiority or equivalence design, the margins for non-inferiority or equivalence must be pre-specified and clinically justified. Regulators will examine the statistical properties of the control group to ensure the comparison is fair and that any observed differences can be confidently attributed to the investigational product rather than methodological artifacts or selection bias.

Statistical Analysis Plan and Sample Size Calculation

A dedicated section of the design review focuses heavily on the statistical analysis plan (SAP) and sample size justification. Regulators require a transparent and reproducible statistical framework that prevents data dredging or p-hacking. They will always ask: "Was the sample size calculated with adequate power to detect a clinically relevant difference?" The design must specify how interim analyses will be handled if they are planned, detailing any stopping rules for futility or safety concerns. Furthermore, the plan must clearly define the hierarchy of datasets (such as the Full Analysis Set vs. the Safety Population) and the methods for handling missing data, ensuring that the final conclusions are robust and not undermined by attrition.

Risk Management and Ethical Considerations

Finally, a robust study design includes a comprehensive risk management plan that addresses both patient safety and data integrity. Regulators will inquire about the mechanisms in place to monitor adverse events, manage protocol deviations, and handle potential data breaches. The design must incorporate ethical considerations, ensuring that the trial minimizes harm to participants while maximizing the potential for scientific and medical gain. This includes the use of independent data monitoring committees (IDMCs) and clear protocols for informed consent processes that are integrated into the design from the outset. By addressing these elements, a study design demonstrates a commitment to ethical standards and regulatory compliance.

Final Verification Checklist

To ensure nothing is overlooked, teams should run through this practical verification list before submitting the protocol for IRB or regulatory review:

  • Is the primary endpoint clinically relevant and measurable?
  • Has the sample size been calculated with sufficient power for the primary hypothesis?
  • Are the inclusion and exclusion criteria clearly defined and justified against the disease state?
  • Is the choice of control group (placebo, active, or historical) rigorously defended?
  • Does the statistical analysis plan specify all datasets, methods for handling missing data, and interim analysis rules?
  • Is there a defined plan for managing adverse events and protocol deviations?
  • Have the site selection criteria ensured that investigators are qualified and capable?

By systematically addressing these questions during the design phase, pharmaceutical teams can significantly reduce the risk of regulatory objections and streamline the path toward approval.

Related reading